A Phase II Study of Oral LBH589 [panobinostat] in Patients With Cutaneous T-Cell Lymphoma and Adult T-Cell Leukemia/Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Panobinostat (Primary)
- Indications Cutaneous T cell lymphoma; Leukaemia
- Focus Therapeutic Use
- 13 Feb 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 11 Jul 2008 New trial record.